Developing a novel oral anti-asthmatic.
RSPR Pharma is a Swedish pharmaceutical company developing an oral anti-asthmatic drug providing mast cell control by inhibiting both induced and basal release of asthma mediators.
Asthma is an inflammatory condition affecting some 300 million people worldwide and despite gold standard therapy (inhaled corticosteroids, which do not target mast cells) only 50% of patients reach asthma control. The RSPR Pharma compound is currently in clinical development and is intended for patients not controlled by corticosteroids.
- CEO Carl-Johan Dalsgaard
- Industry Biotech